EGFR and non-small cell lung carcinoma: Currently, in Japan, gefitinib or erlotinib, first‐generation EGFR‐TKIs, are recommended as first‐line treatment for patients with EGFRm+ advanced NSCLC and a PS of 2, while gefitinib is preferred in patients with a PS of 3–4, based on the evidence of safety and efficacy.5, 28, 29, 30